for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Brainstorm Cell Therapeutics Inc

BCLI.OQ

Latest Trade

3.91USD

Change

-0.02(-0.51%)

Volume

6,878

Today's Range

3.90

 - 

3.92

52 Week Range

2.98

 - 

4.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.93
Open
3.91
Volume
6,878
3M AVG Volume
1.15
Today's High
3.92
Today's Low
3.90
52 Week High
4.50
52 Week Low
2.98
Shares Out (MIL)
22.61
Market Cap (MIL)
88.62
Forward P/E
-4.40
Dividend (Yield %)
--

Next Event

Brainstorm Cell Therapeutics Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference

Latest Developments

More

Brainstorm Cell Therapeutics Posts Q3 Loss Per Share Of $0.25

Brainstorm Cell Therapeutics Says Preetam Shah Appointed CFO

Brainstorm Cell Therapeutics Inc Files Prospectus Relates To Resale By Selling Securityholders Of Up To 842,000 Shares Of Co's Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Brainstorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Industry

Biotechnology & Drugs

Contact Info

1325 Avenue of the Americas Fl 28

+1.201.4880460

http://www.brainstorm-cell.com/

Executive Leadership

Irit Arbel

Independent Chairman of the Board

Chaim Lebovits

President, Chief Executive Officer

Preetam Shah

Chief Financial Officer, Executive Vice President, Treasurer

Ralph Kern

Chief Operating Officer and Chief Medical Officer

Uri Yablonka

Executive Vice President, Chief Business Officer, Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.270

2017

-0.260

2018

-0.700

2019(E)

-0.890
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-718.37
Return on Equity (TTM)
-194.11

Latest News

Latest News

BRIEF-Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health

* BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY

BRIEF-Brainstorm Granted GMP Certification For Marketing-Level Manufacturing Of NurOwn

* BRAINSTORM GRANTED GMP CERTIFICATION FOR A MARKETING-LEVEL MANUFACTURING OF NUROWN® Source text for Eikon: Further company coverage:

BRIEF-Brainstorm Cell Therapuetics names Eyal Rubin CFO

* Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer

BRIEF-Brainstorm reports Q3 loss per share of $0.13

* Q3 loss per share $0.13 Source text for Eikon: Further company coverage:

BrainStorm enrolls first patients in advanced ALS stem cell trial

BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

BRIEF-Brainstorm reports Q2 loss per share of $0.06

* Q2 loss per share $0.06 Source text for Eikon: Further company coverage:

BRIEF-BrainStorm Cell Therapuetics Q2 loss per share $0.06

* Q2 loss per share $0.06 Source text for Eikon: Further company coverage:

BRIEF-Brainstorm announces agreement with University of California Irvine Medical Center

* Brainstorm announces agreement with university of california irvine medical center to participate in phase 3 trial of nurown® in als Source text for Eikon: Further company coverage:

BRIEF-BrainStorm Cell Therapuetics Q1 loss per share $0.10

* BrainStorm announces first quarter 2017 financial results and provides corporate update

BRIEF-Brainstorm Cell Therapuetics Q4 loss per share $0.03

* Brainstorm announces financial results for 2016 and provides business update

BRIEF-Brainstorm Cell Therapuetics Inc increased size of board by two members

* Brainstorm Cell Therapuetics Inc says on February 26, board of co increased size of board by two members - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Brainstorm Cell Therapuetics signs MoU with Tel Aviv Sourasky Medical Center

* Brainstorm Cell Therapuetics-signed MOU with medical research, infrastructure, and health services fund of Tel Aviv Sourasky Medical Center

BRIEF-Brainstorm Cell Therapuetics says signed agreement with CCRM to support market authorization request for nurown

* Brainstorm Cell Therapuetics Inc says has signed an agreement with CCRM to support market authorization request for nurown

BRIEF-City Of Hope to manufacture Nurown for Brainstorm's phase 3 ALS clinical trial

* City Of Hope to manufacture Nurown for Brainstorm's phase 3 ALS clinical trial

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up